Last updated: February 25, 2026
What Is NDC 83324-0155?
NDC 83324-0155 identifies a specific drug formulation listed in the U.S. market. This NDC corresponds to Rimegepant 75 mg tablets, marketed under the brand name Nurtec ODT by Biohaven Pharmaceuticals. It received FDA approval in February 2020 for the acute treatment and preventive management of migraine.
Market Size and Penetration
Prevalence of Migraine in the U.S.
- Affects approximately 12% of the population.
- About 37 million Americans diagnosed; 18 million experience episodic migraines.
- Chronic migraine diagnosed in about 3 million cases.
Market Adoption
- Estimated to capture 5-10% of migraine patients within two years of launch.
- Biohaven reports initial sales exceeding $450 million in 2022, with growth projections based on increase in migraine prevalence and prescription rates.
Competitive Landscape
- Other CGRP inhibitors: Amgen's Aimovig, Eli Lilly's Emgality, and Teva's Ajovy.
- Oral CGRP antagonists like Nurtec ODT and Eli Lilly's Reyvow, which also treat migraines, limit market share for injectables.
- Uptake impacted by formulary access, physician prescribing habits, and insurance coverage.
Pricing and Reimbursement
Current List Price
- Nurtec ODT has a wholesale acquisition cost (WAC) of approximately $1,100 per 30-count package.
- Per tablet cost: ~$36.67.
- Patients with commercial insurance average copay: $10-$30 per prescription.
Insurance Coverage
- Widely reimbursed, with prior authorization in many cases.
- Medicare Part D covers Nurtec ODT, but with utilization management controls.
Patent and Exclusivity
- Patents extend into the late 2020s, preventing generic competition.
- Orphan drug designation accelerated exclusivity periods.
Future Price Trends
Factors Influencing Price Adjustments
- Entry of generics or biosimilars. No generics authorized as of 2023.
- Higher adoption rates may lead to negotiated discounts with payers.
- Potential for tier changes in insurance formularies, affecting patient cost-sharing.
Projected Price Trajectory
| Year |
Estimated Average Price |
Notes |
| 2023 |
$1,100 |
Current WAC, stable as no generics present |
| 2024 |
$1,085 – $1,100 |
Slight discounts expected; payer negotiations likely |
| 2025 |
$1,000 – $1,100 |
Market stabilization; potential early biosimilar delays |
| 2026 |
$950 – $1,050 |
Possible biosimilar introductions in late 2020s' planning phase |
Cost-Effectiveness and Value-Based Pricing
- Payers and providers increasingly shifting towards value-based models.
- Cost per quality-adjusted life year (QALY) for Nurtec ODT remains high relative to generic options, but justifies premium pricing based on efficacy and patient convenience.
Market Outlook
- Continued growth expected through increased awareness and expanded indications.
- Market penetration limited by pricing sensitivity and competition from injectables and alternative oral therapies.
- Biotech companies exploring combination therapies and long-acting formulations to sustain market share.
- Patent protections essential for maintaining premium pricing into the next 3-5 years.
Risks and Opportunities
Risks
- Entry of biosimilars or generics post-patent expiration.
- Evolving treatment guidelines favoring generic therapies.
- Insurance policy changes reducing reimbursement levels.
Opportunities
- Expansion into preventive migraine treatments.
- Combination therapy with other CGRP antagonists.
- Improved formulations reducing dosing frequency.
Key Takeaways
- NDC 83324-0155 refers to Nurtec ODT, a leading oral CGRP receptor antagonist for migraine.
- Market size aligns with the sizable migraine patient base, with rapid adoption since 2020.
- Current pricing remains high, around $1,100 per 30 tablets, with gradual potential decreases due to negotiations and market dynamics.
- Patent protections and clinical positioning support sustained premium pricing into 2025, with price declines likely after patent expiry.
- Growth prospects depend on competitive pressures and evolving healthcare reimbursement policies.
FAQs
1. When will generics likely enter the market for this drug?
It depends on patent expiry and regulatory delays. The primary patents extend into the late 2020s, suggesting generics could appear around 2028-2030.
2. How does Nurtec ODT compare to injectable CGRP therapies?
Nurtec offers oral administration and early onset, appealing for convenience. Injectables may have longer duration but are less preferred by some patients due to injection aversion.
3. What impact will biosimilars have on pricing?
Introduction of biosimilars usually reduces costs through competition, potentially decreasing prices by 20-50% over 2-3 years post-entry.
4. Are insurance companies likely to negotiate discounts?
Yes. Payers negotiate discounts based on formulary inclusion and volume, generally reducing the patient’s out-of-pocket costs.
5. What is the forecasted market share growth for Nurtec ODT?
Market share could grow by 3-5% annually through 2025, driven by increasing migraine prevalence and expanding indications.
Sources
[1] Biohaven Pharmaceuticals. (2022). Nurtec ODT product labeling.
[2] IQVIA. (2023). U.S. Prescription Drug Data.
[3] U.S. Food and Drug Administration. (2020). FDA approval documents for Nurtec ODT.
[4] Centers for Disease Control and Prevention. (2022). Migraine prevalence estimates.
[5] EvaluatePharma. (2023). Prescription drug market forecasts.
